HBK Sorce Advisory’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

HBK Sorce Advisory’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,288	Closed	-$336K	–	775
2022 Q4	$336K	Buy	+5,288	New	+$335K	0.01%	523
2021 Q3	–	Sell	-2,644	Closed	-$204K	–	608
2021 Q2	$204K	Buy	+2,644	New	+$196K	0.01%	552

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

HBK Sorce Advisory's PBE Position: Q1 2023 in Review

HBK Sorce Advisory sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2023, closing a stake of 5,288 shares — an estimated $336K sold.

HBK Sorce Advisory first reported a position in PBE in Q2 2021 and held it in 2 quarters. The position peaked at $336K in Q4 2022. 101 funds tracked by Wall St. Rank hold PBE as of Q1 2023.

HBK Sorce Advisory reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2023 after selling out during the quarter.
HBK Sorce Advisory sold 5,288 Invesco Biotechnology & Genome ETF shares in Q1 2023, an estimated $336K.
HBK Sorce Advisory first reported a position in Invesco Biotechnology & Genome ETF in Q2 2021 and held it in 2 quarters.
HBK Sorce Advisory's Invesco Biotechnology & Genome ETF position peaked at $336K in Q4 2022.
101 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.